Matches in SemOpenAlex for { <https://semopenalex.org/work/W4281836049> ?p ?o ?g. }
Showing items 1 to 88 of
88
with 100 items per page.
- W4281836049 endingPage "e16292" @default.
- W4281836049 startingPage "e16292" @default.
- W4281836049 abstract "e16292 Background: Recent studies have suggested a role for the tumor microbiome in conferring chemoresistance to gemcitabine (GEM) in patients with pancreatic ductal adenocarcinoma (PDAC). One proposed resistance mechanism is the presence of bacterial enzymes that metabolize GEM, but not 5-fluorouracil (5-FU). We therefore assessed the impact of antibiotic receipt in the month before and after initiation of either GEM- or 5-FU-based chemotherapy on PDAC overall survival (OS). Methods: We used the SEER-Medicare database to identify adults >66 years old with stage IV PDAC treated with either first-line GEM or 5-FU between 2007-2017. Antibiotic receipt was defined as a claim for >5 days of oral antibiotics or >1 intravenous antibiotic in the month before or after chemotherapy initiation. Demographic and clinical characteristics were compared using chi-squared and student t-tests, and univariable survival was assessed using Kaplan-Meier methods. Propensity scores (PS) were created to account for potential allocation bias in the receipt of antibiotics. We fit PS-adjusted Cox proportional-hazard models to evaluate the association between antibiotic receipt and OS. Results: We identified 3,990 stage IV PDAC patients treated with first-line GEM-based (n = 3,219) or 5-FU-based (n = 771) chemotherapy, of whom 2,318 (58.1%) received antibiotics. In univariable analyses, antibiotic receipt in the month surrounding chemotherapy initiation was associated with improved median OS in patients treated with GEM (214 days vs 199 days, p = 0.04) but not in patients treated with 5-FU (255 days vs 284 days, P = 0.14). In PS-adjusted multivariable analyses, the significant association between antibiotic receipt and improved OS in patients who received GEM remained (HR 0.89, 95% CI 0.83-0.96). However, no significant association between antibiotic receipt and OS was seen in patients treated with 5-FU (1.10, 95% CI 0.94-1.28). Conclusions: Antibiotic receipt in the month before or after chemotherapy initiation was associated with improved OS in stage IV PDAC patients who received GEM but not 5-FU. These findings support the concept that antibiotics may impact the activity of GEM-metabolizing bacteria proposed to confer chemoresistance. Further studies are needed to characterize the potential role for antibiotics in PDAC treatment.[Table: see text]" @default.
- W4281836049 created "2022-06-13" @default.
- W4281836049 creator A5018088794 @default.
- W4281836049 creator A5018207359 @default.
- W4281836049 creator A5020981991 @default.
- W4281836049 creator A5048973199 @default.
- W4281836049 creator A5049808872 @default.
- W4281836049 creator A5049813870 @default.
- W4281836049 creator A5055627666 @default.
- W4281836049 creator A5082611842 @default.
- W4281836049 date "2022-06-01" @default.
- W4281836049 modified "2023-10-03" @default.
- W4281836049 title "Impact of antibiotics on stage IV pancreatic ductal adenocarcinoma treated with gemcitabine or 5-fluorouracil." @default.
- W4281836049 doi "https://doi.org/10.1200/jco.2022.40.16_suppl.e16292" @default.
- W4281836049 hasPublicationYear "2022" @default.
- W4281836049 type Work @default.
- W4281836049 citedByCount "0" @default.
- W4281836049 crossrefType "journal-article" @default.
- W4281836049 hasAuthorship W4281836049A5018088794 @default.
- W4281836049 hasAuthorship W4281836049A5018207359 @default.
- W4281836049 hasAuthorship W4281836049A5020981991 @default.
- W4281836049 hasAuthorship W4281836049A5048973199 @default.
- W4281836049 hasAuthorship W4281836049A5049808872 @default.
- W4281836049 hasAuthorship W4281836049A5049813870 @default.
- W4281836049 hasAuthorship W4281836049A5055627666 @default.
- W4281836049 hasAuthorship W4281836049A5082611842 @default.
- W4281836049 hasConcept C121608353 @default.
- W4281836049 hasConcept C126322002 @default.
- W4281836049 hasConcept C143998085 @default.
- W4281836049 hasConcept C146357865 @default.
- W4281836049 hasConcept C151730666 @default.
- W4281836049 hasConcept C207103383 @default.
- W4281836049 hasConcept C2776694085 @default.
- W4281836049 hasConcept C2777148230 @default.
- W4281836049 hasConcept C2780210213 @default.
- W4281836049 hasConcept C2780258809 @default.
- W4281836049 hasConcept C2780259306 @default.
- W4281836049 hasConcept C2780456651 @default.
- W4281836049 hasConcept C2781182431 @default.
- W4281836049 hasConcept C44249647 @default.
- W4281836049 hasConcept C501593827 @default.
- W4281836049 hasConcept C50382708 @default.
- W4281836049 hasConcept C526805850 @default.
- W4281836049 hasConcept C71924100 @default.
- W4281836049 hasConcept C86803240 @default.
- W4281836049 hasConcept C89423630 @default.
- W4281836049 hasConcept C90924648 @default.
- W4281836049 hasConceptScore W4281836049C121608353 @default.
- W4281836049 hasConceptScore W4281836049C126322002 @default.
- W4281836049 hasConceptScore W4281836049C143998085 @default.
- W4281836049 hasConceptScore W4281836049C146357865 @default.
- W4281836049 hasConceptScore W4281836049C151730666 @default.
- W4281836049 hasConceptScore W4281836049C207103383 @default.
- W4281836049 hasConceptScore W4281836049C2776694085 @default.
- W4281836049 hasConceptScore W4281836049C2777148230 @default.
- W4281836049 hasConceptScore W4281836049C2780210213 @default.
- W4281836049 hasConceptScore W4281836049C2780258809 @default.
- W4281836049 hasConceptScore W4281836049C2780259306 @default.
- W4281836049 hasConceptScore W4281836049C2780456651 @default.
- W4281836049 hasConceptScore W4281836049C2781182431 @default.
- W4281836049 hasConceptScore W4281836049C44249647 @default.
- W4281836049 hasConceptScore W4281836049C501593827 @default.
- W4281836049 hasConceptScore W4281836049C50382708 @default.
- W4281836049 hasConceptScore W4281836049C526805850 @default.
- W4281836049 hasConceptScore W4281836049C71924100 @default.
- W4281836049 hasConceptScore W4281836049C86803240 @default.
- W4281836049 hasConceptScore W4281836049C89423630 @default.
- W4281836049 hasConceptScore W4281836049C90924648 @default.
- W4281836049 hasIssue "16_suppl" @default.
- W4281836049 hasLocation W42818360491 @default.
- W4281836049 hasOpenAccess W4281836049 @default.
- W4281836049 hasPrimaryLocation W42818360491 @default.
- W4281836049 hasRelatedWork W2012954058 @default.
- W4281836049 hasRelatedWork W2343948994 @default.
- W4281836049 hasRelatedWork W2376347278 @default.
- W4281836049 hasRelatedWork W2410090482 @default.
- W4281836049 hasRelatedWork W2599910524 @default.
- W4281836049 hasRelatedWork W2910998150 @default.
- W4281836049 hasRelatedWork W3008650849 @default.
- W4281836049 hasRelatedWork W3042208798 @default.
- W4281836049 hasRelatedWork W3046481916 @default.
- W4281836049 hasRelatedWork W3196960728 @default.
- W4281836049 hasVolume "40" @default.
- W4281836049 isParatext "false" @default.
- W4281836049 isRetracted "false" @default.
- W4281836049 workType "article" @default.